invIOs INNOVATIVE IMMUNO-ONCOLOGY is a private biotech company founded in 2019 and based in Austria. Their slogan "Developing tomorrow's cancer therapies. Today." reflects their commitment to developing novel cancer therapeutics that activate the immune system to combat cancer. The company focuses on early-stage development, with a special emphasis on moving assets from discovery and pre-clinical development into clinical trials.
Since its launch in 2022 as a spin-out of APEIRON Biologics, invIOs has been actively advancing a targeted pipeline of individualized approaches against solid tumors. Their team of 35 experts covers a wide range of disciplines including R&D, clinical development, CMC, IP, and scouting, all working towards the common goal of transforming patients' lives through innovative cancer treatments.
The company's recent milestone includes securing a grant investment on 05 September 2023 from the Austrian Research Promotion Agency. This investment further validates invIOs' potential in the biotechnology and healthcare sectors, positioning them as a promising player in the field of cancer immunotherapy.